The efficacy and safety of withdrawing versus continuing upadacitinib in maintaining remission ... CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract ...

A total of 454 patients were randomized to either 15 mg or 30 mg upadacitinib once daily. Those in the low-dose group who did not reach the primary endpoint of EASI 90 at 12 weeks were switched to ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...